Parkwalk EIS Funds

Parkwalk EIS Funds have invested in over 70 companies, which have raised in excess of £600m of funding between them since 2010 and over 600 patents protect their technology and processes. As of Q2 2017 the Parkwalk Funds are approximately invested 50% in seed/series ‘A’ and 50% in series ‘B’, ‘C’ or AIM-listed companies. The University of Cambridge Enterprise Funds, University of Oxford Innovation Funds and the University of Bristol Enterprise Funds generally comprise earlier stage investee companies.
Below is a snapshot of the Funds' performance to date.

  • Tax
    Year
  • 2010/11
  • 2011/12
  • 2012/13
  • 2013/14
  • 2014/15
  • 2015/16
  • Realised
    Return
  • 1.79x
  • 0.77x
  • 0.36x
  • 0.32x
  • 0.59x
  • 0.21x
  • Unrealised
    Return
  • 1.12x
  • 0.89x
  • 1.61x
  • 1.59x
  • 1.37x
  • 1.30x
  • Total
    % Return
  • 2.91x
  • 1.66x
  • 1.97x
  • 1.91x
  • 1.96x
  • 1.50x
  • Total % Return inc.
    EIS Reliefs & Fees
  • 3.30x
  • 2.01x
  • 2.43x
  • 2.26x
  • 2.30x
  • 1.80x

Valuations as of 5th April 2017, on all investments made across all Funds per tax year
Past performance is no guide to future performance

Realised Return is cash returned to investors per £ invested
Unrealised Return is value of the balance of  the portfolio including escrow and potential earn-outs on exits
For details of the basis on which fees are charged to the Funds, see the Funds’ prospectuses
Please contact Parkwalk for monthly historical data for each Funds’ performance

  • Parkwalk Fund
  • UK Technology Fund I1
  • UK Technology Fund II2
  • UK Technology Fund III3
  • UK Technology Fund IV3
  • UK Technology Fund V3
  • UK Technology Fund VI
  • UK Technology Fund VII
  • Cambridge Enterprise Fund I3
  • Cambridge Enterprise Fund II3
  • Cambridge Enterprise Fund III3
  • Cambridge Enterprise Fund IV
  • Oxford Isis Fund I
  • Oxford Isis Fund II
  • Oxford Isis Fund III
  • Bristol Enterprise Fund I
  • Parkwalk Opportunities
  • Fund Launch Date
  • Q3 20103
  • Q2 20113
  • Q1 20123
  • Q1 20133
  • Q1 20143
  • Q1 2015
  • Q1 2016
  • Q2 20133
  • Q3 20143
  • Q1 20153
  • Q1 2016
  • Q1 2014
  • Q1 2015
  • Q1 2016
  • Q1 2016
  • evergreen
  • Status
  • Part Exited1
  • Part Exited2
  • Part Exited3
  • Part Exited3
  • Part Exited3
  • Fully Invested
  • Investing
  • Part Exited3
  • Part Exited3
  • Part Exited3
  • Investing
  • Fully Invested
  • Fully Invested
  • Investing
  • Investing
  • Open to investors
  • Gross NAV
  • 218.8%3
  • 227.3%3
  • 102.7%3
  • 93.0%3
  • 121.0%3
  • 119.4%
  • 202.2%3
  • 279.1%3
  • 123.8%3
  • 101.4%
  • 104.6%
  • n/a
  • Net NAV
  • 251.3%3
  • 281.8%3
  • 125.1%3
  • 112.2%3
  • 147.4%3
  • 145.8%
  • 236.0%3
  • 322.4%3
  • 145.9%3
  • 118.5%
  • 121.8%
  • n/a

Net NAV includes tax relief and is stated after the deduction of fees

1 Fund I: September ’14: £0.86 returned to investors in cash for every £1.00 invested (at a cost of £0.78 including fees and charges) on an exit
2 Fund II: June ’14: £1.43 returned to investors in cash for every £1.00 invested (at a cost of £0.73 including fees and charges) on an exit
3 Funds III-V, Cambridge I-III: June ’16: £0.29-£0.96 returned to investors for every £1.00 invested (at a cost of £0.73 including fees and charges) on exits

Exits & IPO’s

As of Q2 2017, two portfolio companies have had extremely successful trade sales and three of our portfolio companies have successfully listed their shares on the Alternative Investment Market of the London Stock Exchange (AIM) – Itaconix (formerly called Revolymer), Horizon Discovery and Xeros.

Parkwalk have also exited the Tracsis plc holding and part-exited the Xeros holding, both for multiple returns.

In total eight of our portfolio companies are AIM-listed.

Parkwalk invested in Tracsis plc in May 2011 at 45p per share (31.5p net of tax reliefs). In June 2014 we exited our holding in a single block trade at 308.5p, representing a nearly 10x tax-free uplift in just three years and two days. Read more here.

The cash return to investors was significantly more than their entire subscription into the UK Tech Fund II. Several of the Fund’s other portfolio companies are also showing progress.

Parkwalk invested in Horizon Discovery in May 2013. The company had a hugely successful IPO in March 2014, raising £40m to list with a market capitalistion of £120m. The floatation was priced at over 100% above the price at which Parkwalk invested.
Parkwalk invested in Eykona in September 2010. In Q1 2014 the company entered into solvent, voluntary liquidation. Parkwalk investors received preference shares in Fuel-3D, a new company formed to exploit the IP generated by Eykona in 3D scanning. Investors also received loss relief on their Eykona investment even though the overall cash return to investors in the UK Tech Fund I is positive.
Parkwalk invested in Itaconix (then named Revolymer) in April 2011, and the company successfully raised £25m when it listed on AIM in July 2012 at a small uplift to our original investment level.
Parkwalk invested in Reinnervate in December 2010, and after a further funding round the company was sold to Reprocell of Japan in July 2014 for a loss. Parkwalk investors received loss relief on their investment even though the overall cash return to investors in the UK Tech Fund II is positive.
Parkwalk first invested in Xeros in October 2010, at 33.0p per share equivalent (26.4p net of initial tax relief). In September 2014 we part-exited for the UK Tech Fund I, returning to investors more than the total cost of their investment in the Fund in under four years.

The UK Tech Funds I and II have now both returned more to investors in cash than the cost of their investments into each Fund.

Parkwalk invested in Clean Air Power in 2013 and 2014. In September 2015 the company’s assets were sold and Parkwalk investors received negligible value. Parkwalk investors received loss relief on their investment.
Parkwalk invested in Mode Diagnostics in May 2012. In Q1 2016 the company was voluntarily struck-off and its assets were sold for a nominal sum.
In September 2015 Vocal IQ was acquired by a large US tech company.
The transaction is subject to a non-disclosure agreement, however it led to a (many) multiple return to Parkwalk investors.
The Parkwalk-managed University of Cambridge Enterprise Fund III invested in Reduse in June 2015. In October 2016 the company entered voluntary liquidation.
In June 2016 Cambridge CMOS Sensors was acquired by ams AG. Transaction details are confidential but the exit generated a multiple return for Parkwalk investors across multiple Funds, and may increase substantially subject to certain milestones.

Email Signature Logos

Past performance is no guide to future performance. Projections and forecasts are also not a reliable indicator of future performance. The performance of a fund can fall as well as rise. Investors may receive back less than originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are highly illiquid and as such there may not be a readily available market to sell such an investment. Tax treatment depends on the individual circumstances of each investor and may be subject to change. Investments referred to in this website are not suitable for all investors. Interested parties are strongly recommended to seek specialist financial and tax advice before investing in any Parkwalk product. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum. Parkwalk is not able to provide advice as to the suitability of investing in a Parkwalk product.